Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493021 · ClinicalTrials.gov registry record · NA
Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions
A NA study, sponsored by R2 Dermatology.
- Completed
- Registry status
- NA
- Development phase
- 137
- Enrollment target
NCT04493021: Completed NA study, sponsored by R2 Dermatology.
NCT04493021 is a NA study that has completed, run by R2 Dermatology. The registered enrollment target is 137 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04493021, a NA study, has completed, sponsored by R2 Dermatology.
- COMPLETED
- Registry status
- NA
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the Dermal Cooling System for lightening of benign pigmented lesions and to assess additional cosmetic benefits.
Primary Outcome
Investigator assessment using Global Aesthetic Improvement Scale (GAIS); graded from "4" (very much improved") to "0" (worse).
Interventions
- DEVICE Dermal Cooling System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2022-05-31 |
| Phase | NA |
What the finished NCT04493021 record still lists
NCT04493021 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Dermal Cooling System is the first listed.
NCT04493021 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04493021 about?
NCT04493021 is a clinical study titled "Evaluation of the Dermal Cooling System for the Enhanced Treatment of Benign Pigmented Lesions and Common Skin Conditions". The purpose of this study is to evaluate the Dermal Cooling System for lightening of benign pigmented lesions and to assess additional cosmetic benefits.
What is the current status of trial NCT04493021?
This trial is currently completed. It is a NA study. The enrollment target is 137 participants. The study started on 2020-07-07. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04493021?
The interventions under investigation include: Dermal Cooling System (DEVICE).
Who is sponsoring clinical trial NCT04493021?
This trial is sponsored by R2 Dermatology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04493021's enrollment target sits among peer trials
137 722nd of 2000 higher than 1,279 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI